What is Horizon Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-04-26), Horizon Therapeutics's share price is R$58.24.
Horizon Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was R$2.32. Hence, Horizon Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is 25.13.
The historical rank and industry rank for Horizon Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
BSP:H1ZN34'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.84 Med: 17.48 Max: 216.77
Current: 26.16
During the past 13 years, Horizon Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 216.77. The lowest was 4.84. And the median was 17.48.
Horizon Therapeutics's Cash Flow from Operations per share for the
three
months ended in Jun. 2023 was R$0.35.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was R$2.32.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Horizon Therapeutics was -25.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 37.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 32.30% per year.
During the past 13 years, Horizon Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.30% per year. The lowest was -3.30% per year. And the median was 37.10% per year.
Horizon Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Horizon Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horizon Therapeutics Price-to-Operating-Cash-Flow Chart
|
Horizon Therapeutics Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
16.69 |
17.43 |
28.34 |
24.53 |
21.28 |
|
Horizon Therapeutics Quarterly Data
|
|
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
13.33 |
10.67 |
21.28 |
22.69 |
23.14 |
Competitive Comparison of Horizon Therapeutics's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Horizon Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Horizon Therapeutics's Price-to-Operating-Cash-Flow falls into.
Horizon Therapeutics Price-to-Operating-Cash-Flow Calculation
Horizon Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 58.24 | / | 2.318 |
| = | 25.13 |
Horizon Therapeutics's Share Price of today is R$58.24.
Horizon Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Horizon Therapeutics (BSP:H1ZN34) Business Description
Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.
Horizon Therapeutics (BSP:H1ZN34) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:H1ZN34 has been successfully added to your